• Home
  • Technology
  • Gaming
  • Entertainment
  • World & Business
  • Science
  • Sports
  • AI
HomeTechnologyGamingEntertainmentWorld & BusinessScienceSportsAI
    • HomeTechnologyGamingEntertainmentWorld & BusinessScienceSportsAI
    • Home
    • Technology
    • Gaming
    • Entertainment
    • World & Business
    • Science
    • Sports
    • AI
    AI
    Announcement

    Kosmos reportedly drafted a drug application section in 4.2 hours

    Edison Scientific reports a first acceptable Nonclinical Overview draft for Population Health Partners, compared with roughly 100 hours of expert time.

    AW
    SR
    ES
    5 Sources, ,

    TLDR

    Edison Scientific reports that Kosmos drafted a Nonclinical Overview in 4.2 hours, compared with roughly 100 expert hours. It also drafted roughly 70% of a pre-IND meeting request submitted to the FDA, with PHP editing. PHP expects preparation for a second program to take about one month instead of four; that saving remains a projection.

    Combined views

    61.3K

    5 Sources, first seen 10h ago

    Combined views

    61.3K

    5 Sources, first seen 10h ago

    358 likes

    Useful links

    usatoday.com

    Edison Scientific and Population Health Partners Partner to Build the Next Generation of Biotech Companies

    edisonscientific.com

    Kosmos: An AI Scientist for Autonomous Discovery

    NVIDIA Developer

    AI-Powered Scientific Discovery With Nemotron
    10h ago
    first seen 10h ago
    358 likes
    18 comments
    171 saves
    51 reposts

    Edison Scientific reports that its Kosmos Regulatory Authoring product produced a first acceptable draft of a Nonclinical Overview for Population Health Partners in 4.2 hours, compared with roughly 100 hours of expert time.

    The section forms part of an Investigational New Drug application, a sponsor’s request to the FDA for permission to dose humans. Edison’s Sept. 30 case study describes specialized Kosmos products customized for PHP’s filing process.

    Kosmos also drafted roughly 70% of a pre-IND meeting request submitted to the FDA, which PHP edited. PHP is bringing Kosmos to a second program and expects preparation to take about one month instead of four. That time saving is a projection in the company’s account.

    Edison Scientific, Inc

    Sentiment

    Positive——Negative

    Summary

    Not enough discussion yet.

    No sentiment analysis available yet.

    Featured Source
    18 comments
    171 saves
    51 reposts

    Useful Links

    usatoday.com

    Edison Scientific and Population Health Partners Partner to Build the Next Generation of Biotech Companies

    Sentiment

    Positive——Negative

    Summary

    Not enough discussion yet.

    No sentiment analysis available yet.

    edisonscientific.com

    Kosmos: An AI Scientist for Autonomous Discovery

    NVIDIA Developer

    AI-Powered Scientific Discovery With Nemotron
    Today's Rank

    —

    Not ranked yet

    Today's Rank

    —

    Not ranked yet

    Useful Links

    usatoday.com

    Edison Scientific and Population Health Partners Partner to Build the Next Generation of Biotech Companies

    edisonscientific.com

    Kosmos: An AI Scientist for Autonomous Discovery

    NVIDIA Developer

    AI-Powered Scientific Discovery With Nemotron

    6 Sources

    edisonscientific.comHow Population Health Partners accelerates its regulatory process with Kosmos
    @EdisonSciWriting an Investigational New Drug (IND) application is a major hurdle for drug developers. It can take a team of specialists three to four months, and mistakes can trigger protocol amendments or clinical holds. In June, we started working with Population Health Partners (PHP) to leverage specialized Kosmos Clinical Protocol Design (“CPD”) and Kosmos Regulatory Authoring (“RA”) products to support PHP’s process of IND preparation. Since then, specially trained Kosmos products produced a first acceptable draft of the Nonclinical Overview in 4.2 hours, against 100 hours of expert time, flagged an error that roughly fifteen human reviewers missed, and authored 70% of the text in a Pre-IND Briefing Meeting Request submitted to FDA. PHP is now bringing Kosmos products to a second program and expects to complete IND preparation in as little as 1 month, instead of the 4 month industry standard. PHP's experts can spend their time reviewing and deciding, not just drafting. The time recovered by Kosmos products means that drugs could make their way to patients faster.
    @SGRodriquesAt FutureHouse, we focused on scientific discovery. However, if we want to actually accelerate progress in medicine, we need to work across the entire R&D stack. We are now deploying specialized Kosmos agents for Clinical Protocol Design and Regulatory Authoring to several of our partners, which can cut months off the amount of time needed to get molecules into the clinic, save companies tens of millions of dollars, and dramatically reduce the likelihood that submissions get stuck at the FDA. Super excited to be able to share this story now, thanks to our work with Population Health Partners, one of the best drug developers in the world and a fantastic development partner for us. The AI-native pharma stack is here now, and the future of medicine is around the corner. Read more:
    @andrewwhite01There's been a lot of hand-waving arguments about how AI will accelerate drug discovery. Here's a concrete 3-month reduction in a real example that accelerated a drug program. It's not thrilling like discovering better targets (which we're working on), but I'm happy with it

    Related

    Edison Scientific Unveils BixBench3 for Biology AI Evaluation

    Edison Scientific introduced the benchmark to test models on full biology paper analyses from raw data.

    6 Sources

    edisonscientific.comHow Population Health Partners accelerates its regulatory process with Kosmos
    @EdisonSciWriting an Investigational New Drug (IND) application is a major hurdle for drug developers. It can take a team of specialists three to four months, and mistakes can trigger protocol amendments or clinical holds. In June, we started working with Population Health Partners (PHP) to leverage specialized Kosmos Clinical Protocol Design (“CPD”) and Kosmos Regulatory Authoring (“RA”) products to support PHP’s process of IND preparation. Since then, specially trained Kosmos products produced a first acceptable draft of the Nonclinical Overview in 4.2 hours, against 100 hours of expert time, flagged an error that roughly fifteen human reviewers missed, and authored 70% of the text in a Pre-IND Briefing Meeting Request submitted to FDA. PHP is now bringing Kosmos products to a second program and expects to complete IND preparation in as little as 1 month, instead of the 4 month industry standard. PHP's experts can spend their time reviewing and deciding, not just drafting. The time recovered by Kosmos products means that drugs could make their way to patients faster.
    @SGRodriquesAt FutureHouse, we focused on scientific discovery. However, if we want to actually accelerate progress in medicine, we need to work across the entire R&D stack. We are now deploying specialized Kosmos agents for Clinical Protocol Design and Regulatory Authoring to several of our partners, which can cut months off the amount of time needed to get molecules into the clinic, save companies tens of millions of dollars, and dramatically reduce the likelihood that submissions get stuck at the FDA. Super excited to be able to share this story now, thanks to our work with Population Health Partners, one of the best drug developers in the world and a fantastic development partner for us. The AI-native pharma stack is here now, and the future of medicine is around the corner. Read more:
    @andrewwhite01There's been a lot of hand-waving arguments about how AI will accelerate drug discovery. Here's a concrete 3-month reduction in a real example that accelerated a drug program. It's not thrilling like discovering better targets (which we're working on), but I'm happy with it